-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
5-Fluorouracil
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/51-21-8.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 51-21-8 |
| Description | Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS). |
Product Information
| Synonyms | 5-FU; Fluorouracil; Adrucil |
| IUPAC Name | 5-fluoro-1H-pyrimidine-2,4-dione |
| Molecular Weight | 130.08 |
| Molecular Formula | C4H3FN2O2 |
| Canonical SMILES | C1=C(C(=O)NC(=O)N1)F |
| InChI | InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9) |
| InChIKey | GHASVSINZRGABV-UHFFFAOYSA-N |
| Boiling Point | 401.4±48.0 °C at 760 mmHg |
| Melting Point | 282-286°C (dec.)(lit.) |
| Flash Point | 196.5±29.6 °C |
| Purity | >98% |
| Density | 1.53 g/cm3 |
| Solubility | Soluble in DMF, DMSO, methanol |
| Appearance | White Crystalline Powder |
| Storage | Store at RT |
| Complexity | 199 |
| Exact Mass | 130.017853 |
| Index Of Refraction | 1.596 |
| In Vitro | 5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC50 value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively. |
| In Vivo | 5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility |
| PSA | 65.72000 |
| Target | Nucleoside Antimetabolite/Analog; HIV; Apoptosis; Endogenous Metabolite |
| Vapor Pressure | 0.0±1.0 mmHg at 25°C |
| XLogP3-AA | -0.9 |
